Novo Nordisk shares plunge 20% after disappointing trial results; Lilly jumps newsthirst.

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy. Hollie Adams | Reuters Shares of Danish pharmaceutical giant Novo Nordisk plummeted roughly 20% on Friday after reporting results in a late-stage trial for its experimental CagriSema weight loss drug that missed expectations. The maker of the wildly popular Wegovy obesity…

Read More